<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03439280</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-079-1501</org_study_id>
    <secondary_id>U1111-1208-3202</secondary_id>
    <nct_id>NCT03439280</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)</brief_title>
  <official_title>A Phase 1/2a Open-label, Dose-Escalation Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Patients With Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, maximum tolerated dose
      (MTD)/recommended phase 2 dose (RP2D) in Phase 1 of the study and to provide a preliminary
      evaluation of the clinical activity of TAK-079 monotherapy in participants with r/r MM in
      Phase 2a of the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called TAK-079. TAK-079 is being tested to treat
      people who have r/r MM. This study will assess the safety, tolerability, efficacy,
      pharmacokinetics, and immunogenicity of TAK-079 monotherapy and will provide a preliminary
      assessment of its activity against MM. The study is designed to consist of 2 phases: Phase 1
      and Phase 2a.

      The study will enroll approximately 42 participants. The study population of Phase 1 will
      consist of approximately 24 participants. Participants in Phase 1 will be assigned to TAK-079
      and dose-escalation will range from 45 mg to 1800 mg.

      In Phase 1, participants will receive premedications 1 to 3 hours prior to the administration
      of TAK-079 on each dosing day, as follows:

        -  Dexamethasone 20 mg

        -  Acetaminophen 650 to 1000 mg

        -  Diphenhydramine 25 to 50 mg

        -  Montelukast 10 mg

      The study population of Phase 2a will consist of approximately 18 participants. Dose and
      premedications for Phase 2a will be based upon review of the available safety, efficacy,
      pharmacokinetic, and pharmacodynamic data from the preceding cohorts of Phase 1.

      This multi-center trial will be conducted in the United States. The overall time to
      participate in this study is 48 months (4 years). In Phase 1, participants who stop treatment
      for any other reason other than PD will continue to have progression-free survival (PFS)
      follow-up at the site every 4 weeks from the last dose of study drug up to 12 months or until
      PD, death, loss to follow-up, consent withdrawal or study termination. Participants will be
      followed 30 days after last dose of study drug or until the start of subsequent alternative
      anti-cancer therapy, whichever occurs first, for a follow up assessment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2018</start_date>
  <completion_date type="Anticipated">October 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 28, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Number of Participants Reporting one or more Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: Number of Participants with Dose-limiting Toxicities (DLTs)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>DLTs will be defined as any of the following events: Grade 4 laboratory abnormalities, except those events that are clearly due to extraneous causes; nonhematologic TEAEs of grade greater than or equal to (&gt;=3) except grade 3 nausea/vomiting, fatigue lasting less than 72 hours, elevation of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) that resolves to grade less than or equal to (&lt;=)1 or baseline within 7 days, injection reaction (IR) that responds to symptomatic treatment; Hematologic TEAEs of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grade &gt;=4, except grade &gt;=3 hemolysis, grade 3 low platelet or higher count with clinically meaningful bleeding; and an incomplete recovery from treatment-related toxicity causing a greater than (&gt;) 2-week delay in the next scheduled injection before the initiation of Cycle 2 will be considered a DLT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: Number of Participants with Grade 3 or Higher TEAEs</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>AE Grades will be evaluated as per NCI CTCAE, version 4.03. Grade 1 scaled as Mild; Grade 2 scaled as Moderate; Grade 3 scaled as severe or medically significant but not immediately life-threatening; Grade 4 scaled as life-threatening consequences; and Grade 5 scaled as death related to AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: Number of Participants with Serious TEAEs</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: Number of Participants with TEAEs Leading to Treatment Discontinuation</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: Number of Participants with TEAEs Leading to Dose Modifications</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: Number of Participants with Clinically Significant Laboratory Values</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: Number of Participants with Clinically Significant Vital Sign Measurements</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2a: Overall Response Rate (ORR)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>ORR is defined as the percentage of participants who achieved a partial response (PR) of 50 percent (%) tumor reduction or better during the study. PR is defined as &gt;=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by &gt;= 90% or to less than (&lt;) 200 milligram per (mg/) 24 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum Observed Serum Concentration for TAK-079</measure>
    <time_frame>Cycle 1 and 2: Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time to Reach the Maximum Observed Serum Concentration (Cmax) for TAK-079</measure>
    <time_frame>Cycle 1 and 2: Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast: Area Under the Serum Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration for TAK-079</measure>
    <time_frame>Cycle 1 and 2: Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: ORR</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>ORR is defined as the percentage of participants who achieved a PR of 50% tumor reduction or better during the study. PR is defined as &gt;=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by &gt;=90% or to &lt;200 mg/24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Minimal Response (MR)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>MR is defined as &gt;=25% but &lt;=49% reduction of serum M-protein and reduction in 24-hour urine M-protein by 50% to 89%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Positive Anti-drug Antibodies (ADA)</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2a: Number of Participants with DLTs</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2a: Number of Participants Reporting one or more TEAEs</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2a: Number of Participants with TEAEs Leading to Dose Modifications</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2a: Number of Participants with TEAEs Leading to Treatment Discontinuation</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2a: Number of Participants with Clinically Significant Laboratory Values</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2a: Number of Participants with Clinically Significant Vital Sign Measurements</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2a: Duration of Response (DOR)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>DOR is the time from date of first documentation of response to date of first documented PD. PD is increase of &gt;=25% from lowest response value in any of following:Serum M-protein(increase must be &gt;=0.5 gram per decilitre[g/dL];serum M component increases &gt;=1 g/dL are sufficient to define relapse if starting M component is &gt;=5 g/dL),and/or urine M-protein(increase must be &gt;=200 mg/24 hour), and/or only in participants without measurable serum and urine M-protein levels, difference between involved/uninvolved free light chain (FLC) levels (increase must be &gt;10 mg/dL), and only in participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow plasma cell percentage (percentage must be &gt;=10%) or definite development of new bone lesions or soft tissue plasmacytomas or increase in size of bone lesions or soft tissue plasmacytomas, and development of hypercalcemia that can be attributed solely to plasma cell proliferative disorder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2a: Progression Free Survival (PFS)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>PFS is time from the date of the first dose until the earliest date of disease progression (PD). PD is increase of &gt;=25% from lowest response value in any of following: Serum M-protein (increase must be &gt;=0.5 g/dL; serum M component increases &gt;=1 g/dL are sufficient to define relapse if starting M component is &gt;=5 g/dL),and/or urine M-protein (increase must be &gt;=200 mg/24 hour), and/or only in participants without measurable serum and urine M-protein levels, difference between involved/uninvolved FLC levels (increase must be &gt;10 mg/dL), and only in participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow plasma cell percentage (percentage must be &gt;=10%) or definite development of new bone lesions or soft tissue plasmacytomas or increase in size of bone lesions or soft tissue plasmacytomas, and development of hypercalcemia that can be attributed solely to plasma cell proliferative disorder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2a: Overall Survival (OS)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>OS is defined as the time from the date of first dose to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2a: Time to Response (TTR)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>TTR is defined as the time from the date of the first dose to the date of the first documentation of response (PR [partial response] or better). PR is defined as &gt;=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by &gt;=90% or to &lt;200 mg/24 hours.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Relapsed/Refractory</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Phase 1 Cohort 1: TAK-079</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-079, injection, subcutaneously, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons. Dose escalation of TAK-079 will range from 45 milligram (mg) to 1800 mg and may be done using a 3 + 3 dose escalation design to determine a MTD and/or RP2D.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2a: TAK-079 TBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-079, injection, subcutaneously, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons. TAK-079 dose for this phase will be determined based on review of the available safety, efficacy, pharmacokinetic, and pharmacodynamic data obtained from the Phase 1 portion of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-079</intervention_name>
    <description>TAK-079 injection.</description>
    <arm_group_label>Phase 1 Cohort 1: TAK-079</arm_group_label>
    <arm_group_label>Phase 2a: TAK-079 TBD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Eastern Cooperative Oncology Group (ECOG) performance status of &lt;=2.

          2. Has received previous myeloma-specific therapy.

          3. Requires additional therapy, as determined by the investigator.

          4. Documentation of r/r MM as defined by the International Myeloma Working Group (IMWG)
             criteria.

          5. For Participants with MM, measurable disease defined as one of the following:

               -  Serum M-protein &gt;=500 mg/dL (&gt;=5 gram per liter [g/L]).

               -  Urine M-protein &gt;=200 mg/24 hours.

               -  In participants without measurable M-protein in serum protein electrophoresis
                  (SPEP) or urine protein electrophoresis (UPEP), a serum FLC assay result with
                  involved FLC level &gt;=10 mg/dL (&gt;=100 milligram per liter [mg/L]), provided serum
                  FLC ratio is abnormal.

          6. Prior therapy should include at least a proteasome inhibitor (PI), an immunomodulatory
             drug (IMid), an alkylating agent, and a steroid and should be refractory or intolerant
             to at least 1 PI and at least 1 IMid.

        Note:

        o Refractory is defined as at least a 25% increase in M-protein or PD during treatment or
        within 60 days after cessation of treatment.

        Exclusion Criteria:

          1. Sensory or motor neuropathy of National Cancer Institute Common Terminology Criteria
             for Adverse Events (NCI CTCAE) Grade &gt;=3.

          2. Have received allogeneic stem cell transplant.

          3. Have received anti-CD38 antibody therapy and do not fulfill a 120-day washout period
             before receiving TAK-079.

          4. Not recovered from adverse reactions to prior myeloma treatment or procedures
             (chemotherapy, immunotherapy, radiation therapy) to NCI CTCAE Grade &lt;=1 or baseline.

          5. Clinical signs of central nervous system (CNS) involvement of MM.

          6. Active chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, active
             HIV, or cytomegalovirus (CMV) infection.

          7. POEMS (Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin
             changes) syndrome, monoclonal gammopathy of unknown significance, smoldering myeloma,
             solitary plasmacytoma, amyloidosis, Waldenstr√∂m macroglobulinemia, or IgM myeloma.

          8. Positive Coombs tests at screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takeda Study Registration Call Center</last_name>
    <phone>+1-844-662-8532</phone>
    <email>globaloncologymedinfo@takeda.com</email>
  </overall_contact>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2018</study_first_submitted>
  <study_first_submitted_qc>February 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2018</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

